A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, "Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide ...

Promising early clinical data about the drugs ERAS-007 and ERAS-601 has led to a trial studying the combination of the two drugs in treating patients with RAS/MAPK pathway-driven cancers. The first ...

Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American Association ...